XORTX stock: XORTX outlines Canadian trial plan before stock results

Published on 10/24/2026 at 03:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

XORTX plans a two-part Canadian study after its October 8 release. For XORTX stock, the second-quarter loss reached USD 1.69 million before November 12 results.

Pipeline and reporting milestones

XORTX outlined a Canadian trial plan for XRx-026 on October 8, 2026.
Net loss reached USD 1.69 million in the second quarter of 2026, compared with USD 808.47 thousand in the first quarter.
The next earnings report is scheduled for November 12, 2026.

XRTX, CA98420Q4051, Illustration mit AI erstellt.

XORTX Therapeutics (ISIN CA98420Q4051) outlined a two-part Canadian study for its XRx-026 gout program on October 8, 2026, according to XORTX Therapeutics. The plan places a Health Canada application alongside the company's planned U.S. regulatory path.

Canadian study adds a milestone

The planned XRX-OXY-102 study will evaluate XORLO, XORTX's proprietary oxypurinol formulation. The first part is planned for Canada, with the company saying this could accelerate clinical data for a future New Drug Application to the U.S. Food and Drug Administration, as detailed by XORTX Therapeutics.

The regulatory step is still a plan rather than a completed filing. That distinction matters because the company remains in clinical development, with XRx-026 at the center of its gout strategy.

What does the plan mean for earnings?

The development program is advancing while losses remain material. TradingView lists a net loss of USD 1.69 million for the second quarter of 2026, compared with USD 808.47 thousand in the first quarter. The comparison shows that clinical progress is occurring alongside higher quarterly losses.

Three dated company milestones

On June 30, 2026, XORTX reported a USD 1.69 million second-quarter net loss through its financial reporting. On September 18, 2026, its investor-relations page listed a planned FDA filing for XRx-026 targeting a USD 700 million-plus U.S. gout market opportunity, according to XORTX Therapeutics. On October 8, 2026, the company outlined the two-part Canadian trial application.

Next reporting date

The next earnings report is scheduled for November 12, 2026, according to TradingView. XORTX was last quoted at USD 0.92 on Nasdaq on October 23, 2026 at 4:00 p.m. ET.

Regulatory progress meets funding pressure

XORTX's Nasdaq listing and Canadian trial plan give investors a clear near-term sequence: regulatory preparation, clinical execution and the November report. The second-quarter loss of USD 1.69 million provides the financial counterweight to the development timeline.

The further course of trading is shown by the continuously updated real-time quote of XORTX stock.